The current valuation multiple appears to be a premium relative to traditional specialty pharma, yet it remains tempered by the inherent risks of isotope supply chain volatility. Investors should monitor whether the forward EV/EBITDA of 8.24 accurately captures the potential for margin compression if reimbursement models shift toward bundled payments.

This decline in capital efficiency warrants further investigation into whether the firm's recent M&A activity is diluting the returns of its core diagnostic franchise. The shift suggests that management may be entering a phase of diminishing marginal returns on invested capital as the competitive landscape for PSMA-targeting agents intensifies.

The elevated DSO of 85 days suggests that the company may be facing extended payment terms from hospital systems, which could pressure liquidity if not managed effectively. This working capital profile is structurally different from traditional drug manufacturers, as the inventory must be moved almost immediately upon production to avoid total loss.

This lack of leverage is a critical differentiator compared to peers, offering management the flexibility to navigate potential supply chain shocks or regulatory reimbursement adjustments without the burden of debt service. Investors should view this as a defensive moat that supports long-term operational stability in a capital-intensive industry.